Literature DB >> 34456134

Natural history of Tay-Sachs disease in sheep.

Brett Story1, Toloo Taghian2, Jillian Gallagher3, Jey Koehler4, Amanda Taylor5, Ashley Randle1, Kayly Nielsen1, Amanda Gross1, Annie Maguire6, Sara Carl1, Siauna Johnson1, Deborah Fernau3, Elise Diffie1, Paul Cuddon7, Carly Corado8, Sundeep Chandra8, Miguel Sena-Esteves9, Edwin Kolodny10, Xuntian Jiang11, Douglas Martin12, Heather Gray-Edwards13.   

Abstract

Tay-Sachs disease (TSD) is a fatal neurodegenerative disease caused by a deficiency of the enzyme β-N-acetylhexosaminidase A (HexA). TSD naturally occurs in Jacob sheep is the only experimental model of TSD. TSD in sheep recapitulates neurologic features similar to juvenile onset and late onset TSD patients. Due to the paucity of human literature on pathology of TSD, a better natural history in the sheep TSD brain, which is on the same order of magnitude as a child's, is necessary for evaluating therapy and characterizing the pathological events that occur. To provide clinicians and researchers with a clearer understanding of longitudinal pathology in patients, we compare spectrum of clinical signs and brain pathology in mildly symptomatic (3-months), moderately symptomatic (6-months), or severely affected TSD sheep (humane endpoint at ~9-months of age). Increased GM2 ganglioside in the CSF of TSD sheep and a TSD specific biomarker on MRS (taurine) correlate with disease severity. Microglial activation and reactive astrocytes were observed globally on histopathology in TSD sheep with a widespread reduction in oligodendrocyte density. Myelination is reduced primarily in the forebrain illustrated by loss of white matter on MRI. GM2 and GM3 ganglioside were increased and distributed differently in various tissues. The study of TSD in the sheep model provides a natural history to shed light on the pathophysiology of TSD, which is of utmost importance due to novel therapeutics being assessed in human patients.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Large animal model; Neurodegeneration; Sheep; Tay-Sachs; Translational; Veterinary

Mesh:

Year:  2021        PMID: 34456134      PMCID: PMC8811770          DOI: 10.1016/j.ymgme.2021.08.009

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.204


  51 in total

1.  MR imaging and proton spectroscopy of neuronal injury in late-onset GM2 gangliosidosis.

Authors:  Matilde Inglese; Annette O Nusbaum; Gregory M Pastores; John Gianutsos; Edwin H Kolodny; Oded Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2005-09       Impact factor: 3.825

2.  AAV-mediated gene delivery attenuates neuroinflammation in feline Sandhoff disease.

Authors:  Allison M Bradbury; Tiffany A Peterson; Amanda L Gross; Stephen Z Wells; Victoria J McCurdy; Karen G Wolfe; John C Dennis; Brandon L Brunson; Heather Gray-Edwards; Ashley N Randle; Aime K Johnson; Edward E Morrison; Nancy R Cox; Henry J Baker; Miguel Sena-Esteves; Douglas R Martin
Journal:  Neuroscience       Date:  2016-10-26       Impact factor: 3.590

3.  Prenatal diagnosis and fetal pathology of Tay-Sachs disease.

Authors:  S Higami; K Nishizawa; K Omura; K Sugimoto; G Isshiki
Journal:  Tohoku J Exp Med       Date:  1976-04       Impact factor: 1.848

4.  Pathology of GM2 gangliosidosis in Jacob sheep.

Authors:  B F Porter; B C Lewis; J F Edwards; J Alroy; B J Zeng; P A Torres; K N Bretzlaff; E H Kolodny
Journal:  Vet Pathol       Date:  2010-12-01       Impact factor: 2.221

5.  Widespread correction of central nervous system disease after intracranial gene therapy in a feline model of Sandhoff disease.

Authors:  V J McCurdy; H E Rockwell; J R Arthur; A M Bradbury; A K Johnson; A N Randle; B L Brunson; M Hwang; H L Gray-Edwards; N E Morrison; J A Johnson; H J Baker; N R Cox; T N Seyfried; M Sena-Esteves; D R Martin
Journal:  Gene Ther       Date:  2014-12-04       Impact factor: 5.250

6.  New cases of adult-onset Sandhoff disease with a cerebellar or lower motor neuron phenotype.

Authors:  C C S Delnooz; D J Lefeber; S M C Langemeijer; S Hoffjan; G Dekomien; M J Zwarts; B G M Van Engelen; R A Wevers; H J Schelhaas; B P C van de Warrenburg
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-09       Impact factor: 10.154

7.  Novel Biomarkers of Human GM1 Gangliosidosis Reflect the Clinical Efficacy of Gene Therapy in a Feline Model.

Authors:  Heather L Gray-Edwards; Debra S Regier; Jamie L Shirley; Ashley N Randle; Nouha Salibi; Sarah E Thomas; Yvonne L Latour; Jean Johnston; Gretchen Golas; Annie S Maguire; Amanda R Taylor; Donald C Sorjonen; Victoria J McCurdy; Peter W Christopherson; Allison M Bradbury; Ronald J Beyers; Aime K Johnson; Brandon L Brunson; Nancy R Cox; Henry J Baker; Thomas S Denney; Miguel Sena-Esteves; Cynthia J Tifft; Douglas R Martin
Journal:  Mol Ther       Date:  2017-02-22       Impact factor: 11.454

Review 8.  The clinical aspects of adult hexosaminidase deficiencies.

Authors:  A Federico; S Palmeri; A Malandrini; G Fabrizi; M Mondelli; G C Guazzi
Journal:  Dev Neurosci       Date:  1991       Impact factor: 2.984

9.  Murine Sialidase Neu3 facilitates GM2 degradation and bypass in mouse model of Tay-Sachs disease.

Authors:  Volkan Seyrantepe; Secil Akyildiz Demir; Zehra Kevser Timur; Johanna Von Gerichten; Christian Marsching; Esra Erdemli; Emin Oztas; Kohta Takahashi; Kazunori Yamaguchi; Nurselin Ates; Buket Dönmez Demir; Turgay Dalkara; Katrin Erich; Carsten Hopf; Roger Sandhoff; Taeko Miyagi
Journal:  Exp Neurol       Date:  2017-09-30       Impact factor: 5.330

10.  Patient and caregiver perspectives on burden of disease manifestations in late-onset Tay-Sachs and Sandhoff diseases.

Authors:  Nicole Lyn; Ruth Pulikottil-Jacob; Camille Rochmann; Robert Krupnick; Chad Gwaltney; Nick Stephens; Julie Kissell; Gerald F Cox; Tanya Fischer; Alaa Hamed
Journal:  Orphanet J Rare Dis       Date:  2020-04-15       Impact factor: 4.123

View more
  1 in total

Review 1.  The Translational Benefits of Sheep as Large Animal Models of Human Neurological Disorders.

Authors:  Samantha J Murray; Nadia L Mitchell
Journal:  Front Vet Sci       Date:  2022-02-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.